AAV Production In Culture Biosciences' 250mL Bioreactors

By Rebecca Du, Hannah Monroe, Kris Tyner, Jean-Marc Guedon, Kat Kozyrytska, Elena Cant, and Darcy Birse

Scientists working with adeno-associated viruses (AAVs) and advanced therapies are using large-scale explorations of design spaces to identify key process parameters and address the challenges associated with bringing these therapies to market. The majority of gene therapy products are delivered by replication incompetent viral vectors, and of those vectors, the most frequently used vehicle is AAV. Despite the availability of production methods, AAV vectors are still difficult to manufacture at large scale.

Explore this demonstration of an AAV upstream process in Culture Biosciences' 250mL proprietary bioreactors, as well as an example of using process optimization to increase the fraction of full AAV capsids.